Omalizumab is suitable for asthmatics with, in particular, perennial allergen sensitization, exacerbations in the previous 12 months, total IgE levels up to 1,500 IU/mL, blood eosinophils ≥ 260/mL, and childhood-onset asthma. Here, IGHE is linked to asthma.